EUVIMEDEUVIMED entdecken
Multizentrische Studie

Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance

Haruka Nakatani, Hayato Kawachi, Tadaaki Yamada, Naoki Furuya, Hisashi Tanaka, Akihiro Yoshimura, Tomohiro Oba, Makoto Hibino, Takahito Fukuda, Yasuhiro Goto, Akira Nakao, Shinsuke Ogusu und 8 weitere

Anticancer Research · 2026

DOI: 10.21873/anticanres.18159 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Anticancer Research, 2026. Verfasst von Haruka Nakatani und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Cachexia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Drug Resistance, Neoplasm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CachexiaCarcinoma, Non-Small-Cell LungLung NeoplasmsDrug Resistance, NeoplasmProtein Kinase InhibitorsImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleErbB ReceptorsMaleRetrospective StudiesMutationMiddle AgedAgedTreatment OutcomePrognosis

Stichwörter der Autor:innen

Cancer cachexiaepidermal growth factor receptor-mutant non-small cell lung cancerepidermal growth factor receptor-tyrosine kinase inhibitor resistanceimmune checkpoint inhibitors

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, human

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan; tayamada@koto.kpu-m.ac.jp.
  • Division of Respiratory Medicine, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan.
  • Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
  • Department of Respiratory Medicine, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan.

Zitieren

APA

Nakatani, H., Kawachi, H., Yamada, T., Furuya, N., Tanaka, H., Yoshimura, A., Oba, T., Hibino, M., Fukuda, T., Goto, Y., Nakao, A., Ogusu, S., Okazaki, Y., Harada, T., Ota, T., Masubuchi, K., Mikami, K., Hata, T., Morimoto, K., & Takayama, K. (2026). Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance. Anticancer Research. https://doi.org/10.21873/anticanres.18159

Vancouver

Nakatani H, Kawachi H, Yamada T, Furuya N, Tanaka H, Yoshimura A, et al. Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance. Anticancer Research. 2026. doi:10.21873/anticanres.18159

BibTeX
@article{Nakatani2026,
  author = {Nakatani, Haruka and Kawachi, Hayato and Yamada, Tadaaki and Furuya, Naoki and Tanaka, Hisashi and Yoshimura, Akihiro and Oba, Tomohiro and Hibino, Makoto and Fukuda, Takahito and Goto, Yasuhiro and Nakao, Akira and Ogusu, Shinsuke and Okazaki, Yuta and Harada, Taishi and Ota, Takayo and Masubuchi, Ken and Mikami, Koji and Hata, Tae and Morimoto, Kenji and Takayama, Koichi},
  title = {Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR -mutant NSCLC After TKI Resistance},
  journal = {Anticancer Research},
  year = {2026},
  doi = {10.21873/anticanres.18159}
}
Kostenlos starten →